Rain Oncology Inc. stock is up 11.65% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November.
Rain Therapeutics Inc. engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2. The company is also developing RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers.